

Daily evidence digest

24 January 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Neutralising antibodies following CoronaVac and Comirnaty (Pfizer), clinical severity of Omicron, post-acute COVID-19 (long COVID) in Europe

Peer reviewed journals featured:

- Observational studies on:
 - Neutralising antibodies against variants after CoronaVac or Comirnaty (Pfizer) vaccination [here](#) and [here](#)
 - Early assessment of the clinical severity of the Omicron variant in South Africa [here](#)
 - Control and mitigation strategies in the second COVID-19 wave in Spain and Italy [here](#)
- An editorial on post-acute COVID-19 syndrome in children and adolescents [here](#)
- Commentary on Europe's approach to post-acute COVID-19 syndrome (long COVID) [here](#)

Letters and correspondence discussed:

- Omicron sensitivity to molnupiravir and nirmatrelvir [here](#)
- Comparison of mRNA vaccines on breakthrough SARS-CoV-2 infections, hospitalisations, and death during the Delta-predominant period [here](#)
- Quantifying transmission risk of SARS-CoV-2 in different situations [here](#)
- Seroprevalence of antibodies specific to receptor binding domain of SARS-CoV-2 and vaccination among adults in Los Angeles [here](#)

Pre-peer review articles featured:

- Omicron infection of human airway and alveolar cells [here](#)
- Molecular basis of broad neutralisation against SARS-CoV-2 variants by a human antibody [here](#)
- Neutralising response against Omicron variant in Sputnik V vaccinated individuals [here](#)

News and blogs

- England prepares to ease plan B restrictions [here](#)

[Click here](#) to subscribe to the daily evidence digest.